• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Kewaunee Scientific Corporation (Amendment)

    3/10/23 1:24:22 PM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email
    SC 13D/A 1 zucker20230310_sc13da.htm SCHEDULE 13D/A zucker20230310_sc13da.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington D.C. 20549

     


     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     


     

    Kewaunee Scientific Corporation

    (Name of Issuer)

     

    Common Stock, $2.50 par value

    (Title of Class of Securities)

     

    492854104

    (CUSIP Number)

     

    Anita G. Zucker, as Trustee of

    The Article 6 Marital Trust

    c/o The InterTech Group, Inc.

    4838 Jenkins Avenue

    North Charleston, SC 29405

    843-744-5174

     

    With copies to:

    Robert Johnston

    The InterTech Group, Inc.

    4838 Jenkins Avenue

    North Charleston, SC 29405

    843-744-5174

    Christopher J. Hubbert, Esq.

    Kohrman Jackson & Krantz LLP

    1375 E. Ninth Street, 29th Floor

    Cleveland, OH 44114

    216-696-8700

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    March 8, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    1 of 4

     

     

    1

    NAME OF REPORTING PERSONS

     

    Anita G. Zucker, as Trustee of The Article 6 Marital Trust

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

    (a)  
    (b)  

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION


    United States of America

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    7

    SOLE VOTING POWER

     

    221,361 shares of common stock

    8

    SHARED VOTING POWER


    0

    9

    SOLE DISPOSITIVE POWER

     

    221,361 shares of common stock

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    221,361 shares of common stock

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.8%

    14

    TYPE OF REPORTING PERSON

     

    IN

    2 of 4

     

     

    Item 1. Security and Issuer.

     

    This Amendment No. 1 to Schedule 13D relates to the common stock, $2.50 par value (the “Shares”), of Kewaunee Scientific Corporation (“Kewaunee”) owned by Anita G. Zucker as the Trustee of The Article 6 Marital Trust under The First Amended and Restated Jerry Zucker Revocable Trust dated April 2, 2007 (the “Trust”). This amendment supplements Mrs. Zucker’s initial Schedule 13D filed on October 30, 2019.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    The Shares reported in this Schedule 13D were purchased by the Trust using its available funds. The total amount paid by the Trust was $620,534.

     

    Item 4. Purpose of Transaction.

     

    The Trust acquired the Shares for investment purposes.

     

    Item 5. Interest in Securities of the Issuer.

     

    The Trust owns 221,361 Shares, or 7.8% of Kewaunee’s outstanding Shares based on 2,830,200 Shares outstanding. Mrs. Zucker, as trustee of the Trust, has sole voting, investment and dispositive power with respect to the Trust’s Shares.

     

    The Trust acquired the 39,440 Shares listed in the table below in open market transactions through its broker. Neither Mrs. Zucker nor the Trust has effected any other transactions in the Shares of Kewaunee during the past sixty days.

     

    Date

    Shares Acquired

    Price Per Share

    03/08/2023

    21,661

     $15.515

    02/27/2023

    7,787

     $15.658

    02/24/2023

    24

     $15.665

    02/23/2023

    21

     $15.665

    02/22/2023

    108

     $15.800

    02/16/2023

    508

     $15.551

    02/15/2023

    301

     $15.618

    02/14/2023

    1,251

     $15.629

    02/06/2023

    586

     $16.278

    02/02/2023

    560

     $16.217

    02/01/2023

    111

     $16.216

    01/31/2023

    606

     $16.512

    01/30/2023

    440

     $16.650

    01/27/2023

    298

     $16.509

    01/26/2023

    961

     $16.470

    01/25/2023

    86

     $16.394

    01/23/2023

    300

     $16.515

    01/20/2023

    262

     $16.511

    01/19/2023

    100

     $16.445

    01/18/2023

    3,469

     $16.471

     

    3 of 4

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated March 10, 2023

    /s/ Anita G. Zucker

     
     

    By Anita G. Zucker, as Trustee for

    The Article 6 Marital Trust

     

    4 of 4
    Get the next $KEQU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    SEC Filings

    See more
    • SEC Form SD filed by Kewaunee Scientific Corporation

      SD - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      5/9/25 10:54:08 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 144 filed by Kewaunee Scientific Corporation

      144 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      3/31/25 4:23:01 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form 10-Q filed by Kewaunee Scientific Corporation

      10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

      3/14/25 10:22:53 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pyle Margaret B was granted 1,896 shares (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 1:33:49 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Russell John was granted 1,896 shares, increasing direct ownership by 6% to 34,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:58:43 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M was granted 1,896 shares, increasing direct ownership by 10% to 20,396 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      5/9/25 10:56:19 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      4/7/25 10:57:11 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/24/25 4:32:54 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

      4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

      3/18/25 3:20:26 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      11/1/24 9:14:13 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 11:44:29 AM ET
      $KEQU
      Medical Specialities
      Industrials
    • SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

      SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

      2/9/24 9:59:14 AM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kewaunee Scientific Announces Amendment to Share Repurchase Program

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced an amendment to its existing share repurchase program. On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the "Company") amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended (the "Program"), which does not

      3/12/25 5:08:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2025

      STATESVILLE, N.C., Feb. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its third quarter fiscal year 2025 financial results on Wednesday, March 12, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's produc

      2/26/25 5:21:00 PM ET
      $KEQU
      Medical Specialities
      Industrials

    $KEQU
    Financials

    Live finance-specific insights

    See more
    • Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

      STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

      3/12/25 4:16:00 PM ET
      $KEQU
      Medical Specialities
      Industrials
    • Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

      STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

      12/11/24 4:04:00 PM ET
      $KEQU
      Medical Specialities
      Industrials